Seminars in Nephrology
Volume 29, Issue 5 , Pages 512-523 , September 2009

Can Comprehensive Lifestyle Change Alter the Course of Chronic Kidney Disease?

  • Katherine R. Tuttle, MD

      Affiliations

    • Providence Medical Research Center at Sacred Heart Medical Center, Spokane, WA
    • Division of Nephrology, Department of Medicine, University of Washington School of Medicine, Spokane and Seattle, WA
    • Corresponding Author InformationAddress reprint requests to Katherine R. Tuttle, MD, Providence Medical Research Center, 104 W. 5th Ave, Suite 350E, Spokane, WA 99204
    • ,
  • Duane Sunwold

      Affiliations

    • Inland Northwest Culinary Academy, Spokane Community College, Spokane, WA
    • ,
  • Holly Kramer, MD, MPH

      Affiliations

    • Department of Preventive Medicine, Loyola Medical Center, Maywood, IL
    • Division of Nephrology and Hypertension, Department of Medicine, Loyola Medical Center, Maywood, IL

References 

  1. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652–659
  2. Hostetter TH, Meyer TW, Rennke HG, Brenner BM. Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int. 1986;30:509–517
  3. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A. 1985;82:5963–5967
  4. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med. 1991;324:1626–1632
  5. Tuttle KR, Bruton JL. Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int. 1992;42:167–173
  6. Tuttle KR, Puhlman ME, Cooney SK, Short RA. Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes. Am J Physiol Renal Physiol. 2002;282:F103–F112
  7. Uribarri J, Tuttle KR. Advanced glycation end products and nephrotoxicity of high protein diets. Clin J Am Soc Nephrol. 2006;1:1293–1299
  8. Finot PA. Historical perspective of the Maillard reaction in food science. Ann N Y Acad Sci. 2005;1043:1–8
  9. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates N epsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest. 1999;104:103–113
  10. Anderson MM, Heinecke JW. Production of N epsilon-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase (A role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation). Diabetes. 2003;52:2137–2143
  11. Silbiger S, Crowley S, Shan Z, Brownlee M, Satriano J, Schlondorff D. Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int. 1993;43:853–864
  12. Mott JD, Khalifah RG, Nagase H, Shield CF, Hudson JK, Hudson BG. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int. 1997;52:1302–1312
  13. Krishnamurti U, Rondeau E, Sraer JD, Michael AF, Tsilibary EC. Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem. 1997;272:27966–27970
  14. Charonis AS, Tsilbary EC. Structural and functional changes of laminin and type IV collagen after nonenzymatic glycation. Diabetes. 1992;41:S49–S51
  15. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol. 2003;14:S241–S245
  16. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol. 2004;165:2033–2043
  17. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem. 2001;81:102–113
  18. Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM, et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology. 2002;143:4907–4915
  19. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104:1287–1291
  20. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci. 2005;1043:461–466
  21. Tuttle KR, Johnson EC, Cooney SK, Anderberg RJ, Johnson EK, Clifton GD, et al. Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney Int. 2005;67:953–968
  22. Tuttle KR, Anderberg R, Cooney S, Meek R. Oxidative stress mediates protein kinase C activation and advanced glycation end product formation in a mesangial cell model of diabetes and high protein diet. Am J Nephrol. 2009;29:171–180
  23. Cai W, Gao QD, Zhu L, Peppa M, He CJ, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med. 2002;8:337–346
  24. Cai W, He JC, Zhu L, Peppa M, Lu C, Uribarri J, et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation. 2004;110:285–291
  25. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596–15601
  26. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14:728–731
  27. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis. 2004;43:690–695
  28. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000;11:1656–1666
  29. Wrone EM, Carnethon MR, Palaniappan L, Fortmann SP. Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:580–587
  30. Knight EL, Stampfer MJ, Hankinson SE, Spiegelman D, Curhan GC. The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann Intern Med. 2003;138:460–467
  31. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM, et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int. 1998;54:203–209
  32. Bernstein AM, Treyzon L, Zhaoping L. Are high-protein diet, vegetable-based diets safe for kidney function? (A review of the literature). J Am Diet Assoc. 2007;17:644–650
  33. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348:2082–2090
  34. Yancy WS, Olsen MK, Guyton JR, Bakst RP, Westman EC. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med. 2004;140:769–777
  35. Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab. 2003;88:1617–1623
  36. Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004;140:778–785
  37. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124:627–632
  38. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31:954–961
  39. Pan Y, Guo LL, Hui MJ. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:660–666
  40. Fouque D, Laville M, Boissel JP, Chifflet R, Labeeuw M, Zech PY. Controlled low protein diets in chronic renal insufficiency: meta-analysis. BMJ. 1992;304:216–220
  41. Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure. Nephrol Dial Transplant. 2000;15:1986–1992
  42. Fouque D, Laville M, Boissel JP. Low protein diets for chronic kidney disease in non-diabetic adults. Cochrane Database Syst Rev. 2006;2:CD001892
  43. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease (Modification of diet in renal disease study group). N Engl J Med. 1994;330:877–884
  44. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? (Modification of diet in renal disease study group). J Am Soc Nephrol. 1999;10:2426–2439
  45. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62:220–228
  46. Dietary intake of ten key nutrients for public health, United States: 1999-2000 (Advance data report no. 334). www.cdc.gov/nchs/data/ad/ad334.pdf[cited 2008 December]
  47. National Academy of Sciences, Institute of Medicine. Dietary reference intakes for energy, carbohydrates, fiber, fat, fatty acids, cholesterol, protein and amino acids (Macronutrients). Chapter 8 Washington, DC: The National Academy Press; 2002;
  48. American Diabetes Association. ADA standards of medical care in diabetes—2008. Diabetes Care. 2008;31:S20–S21
  49. American Heart Association. Step I, step II, and TLC diets. [cited 2008 December] http://www.americanheart.org/presenter.jhtml?identifier=47642008;
  50. Hamazaki T, Takazakura E, Osawa K, Urakaze M, Yano S. Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester. Lipids. 1990;9:541–545
  51. Dullart RP, Beusekamp BJ, Meijer S, Hoogenberg K, van Doormaal JJ, Sluiter WJ. Long-term effects of linoleic-acid-enriched diet on albuminuria and lipid levels in type 1 (insulin-dependent) diabetic patients with elevated urinary albumin excretion. Diabetologia. 1992;35:165–172
  52. Bouhanick B, Suraniti S, Berrut G, Bled F, Simard G, Lejeune JJ, et al. Relationship between fat intake and glomerular filtration rate in normotensive insulin-dependent diabetic patients. Diabetes Metab. 1995;21:168–172
  53. Rossing P, Hansen BV, Nielsen FS, Myup B, Holmer G, Parving HH. Fish oil in diabetic nephropathy. Diabetes Care. 1996;19:1214–1219
  54. Mollsten A, Dahlquist G, Stattin Eva-Lena, Rudberg S. Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. Diabetes Care. 2001;24:805–811
  55. National Kidney Foundation. KDOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(Suppl 3):S90–S95
  56. Kris-Etherton P, William H, Appel L. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–2757
  57. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet (DASH-Sodium Collaborative Research Group). N Engl J Med. 2001;344:3–10
  58. He J, Gu D, Wu X, Chen J, Duan X, Chen J, et al. Effect of soybean protein on blood pressure: a randomized, controlled trial. Ann Intern Med. 2005;143:1–9
  59. Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER, et al. OmniHeart Collaborative Research Group Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005;294:2455–2464
  60. Azadbakht L, Shakerhosseini R, Atabak S, Jamshidian M, Mehrabi Y, Esmaill-Zadeh A. Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type II diabetes with nephropathy. Eur J Clin Nutr. 2003;57:1292–1294
  61. Pecis M, Azevedo M, Gross J. Chicken and fish diet reduces glomerular hyperfiltration in IDDM patients. Diabetes Care. 1994;17:665–672
  62. Jibani MM, Bloodworth LL, Foden E, Griffiths KD, Galpin OP. Predominantly vegetarian diet in patients with incipient and early clinical diabetic nephropathy: effects on albumin excretion rate and nutritional status. Diabetic Med. 1991;8:949–953
  63. Cutler JA, Obarzanek E. Nutrition and blood pressure: is protein one link? (Toward a strategy of hypertension prevention). Ann Intern Med. 2005;143:74–75
  64. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA. 2007;298:2028–2037
  65. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2007;73:19–33
  66. Muntner P, Winston J, Uribarri J, Mann D, Fox CS. Overweight, obesity, and elevated cystatin C levels in adults in the United States. Am J Med. 2008;121:341–348
  67. Hsu C-Y, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–28
  68. World Health Organization (WHO). Obesity: preventing and managing the global epidemic: report of a WHO consultation on obesity, Geneva, June 3-5, 1997. Geneva: World Health Organization; 1998;
  69. Elsayed EF, Tighiouart H, Weiner DE, Griffith J, Salem D, Levey AS, et al. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis. 2008;52:49–57
  70. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Phys. 2008;294:F685–F696
  71. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898–918
  72. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–619
  73. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319–327
  74. Anonymous KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease (Guideline 5: nutritional management in diabetes and chronic kidney disease). Am J Kidney Dis. 2007;49:S95–S107
  75. Kramer H, Tuttle KR, Leehey D, Luke A, Durazo-Arvizu R, Shoham D, et al. Obesity management in adults with chronic kidney disease. Am J Kidney Dis. 2009;53:151–165
  76. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Clinical Efficacy Assessment Subcommittee of the American College of Physicians (Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians). Ann Intern Med. 2005;142:525–531
  77. Chen J, Muntner P, Hamm LL, Batuman V, Fonseca V, Whelton PK, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14:469–477
  78. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174
  79. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease?. J Am Soc Nephrol. 2004;15:2775–2791
  80. Tuttle KR. Renal manifestations of the metabolic syndrome. Nephrol Dial Transplant. 2005;20:861–864
  81. Packard DP, Milton JE, Shuler LA, Short RA, Tuttle KR. Implications of chronic kidney disease for dietary treatment of cardiovascular disease. J Renal Nutr. 2006;16:259–268
  82. Eckel RH. Clinical practice (Nonsurgical management of obesity in adults). N Engl J Med. 2008;358:1941–1950
  83. Venkataraman R, Sanderson B, Bittner V. Outcomes in patients with chronic kidney disease undergoing cardiac rehabilitation. Am Heart J. 2005;150:1140–1146
  84. Heiwe S, Clyne N, Tollback A, Borg K. Effects of regular resistance training on muscle histopathology and morphometry in elderly patients with chronic kidney disease. Am J Phys Med Rehabil. 2005;84:865–874
  85. Moinuddin I, Leehey DJ. A comparison of aerobic exercise and resistance training in patients with and without chronic kidney disease. Adv Chronic Kidney Dis. 2008;15:83–96
  86. Chuahirun T, Wesson DE. Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite angiotensin converting enzyme inhibition. Am J Kidney Dis. 2002;39:376–382
  87. Phisitkul K, Hegazy K, Chuahirun T, Hudson C, Simoni J, Rajab H, et al. Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am J Med Sci. 2008;335:284–291
  88. Schaeffner ES, Kurth T, de Jong PE, Glynn RJ, Buring JE, Gaziano M. Alcohol consumption and the risk of renal dysfunction in apparently healthy men. Arch Intern Med. 2005;165:1048–1053
  89. Knight EL, Stampfer MJ, Rimm EB, Hankinson SE, Curhan GC. Moderate alcohol intake and renal function decline in women: a prospective study. Nephrol Dial Transplant. 2003;18:1549–1554

PII: S0270-9295(09)00103-X

doi: 10.1016/j.semnephrol.2009.06.008

Seminars in Nephrology
Volume 29, Issue 5 , Pages 512-523 , September 2009

Article Tools

* Image Usage & Resolution